Common Contracts

EX-10.11 16 d555750dex1011.htm EX-10.11 TCR2 THERAPEUTICS INC. AMENDED AND RESTATED CONSULTING AGREEMENT

Consulting Agreement • May 5th, 2020 • Massachusetts

• Contract Type
  Consulting Agreement
• Filed
  May 5th, 2020
• Jurisdiction
  Massachusetts

This Amended and Restated Consulting Agreement (the “Agreement”), made this 9th day of May, 2017 (“Effective Date”), is entered into by TCR2 Therapeutics Inc., a Delaware corporation (the “Company”), Mitchell Finer (the “Dr. Finer”), and Pattern Recognition Ventures (the “Consultant” and, collectively with the Company and Dr. Finer, the “Parties”).

TCR2 THERAPEUTICS INC. AMENDED AND RESTATED CONSULTING AGREEMENT

Consulting Agreement • December 28th, 2018 • Tcr2 Therapeutics Inc. • Biological products, (no disgnostic substances) • Massachusetts

• Contract Type
  Consulting Agreement
• Filed
  December 28th, 2018
• Company
  Tcr2 Therapeutics Inc.
• Industry
  Biological products, (no disgnostic substances)
• Jurisdiction
  Massachusetts

This Amended and Restated Consulting Agreement (the “Agreement”), made this 9th day of May, 2017 (“Effective Date”), is entered into by TCR2 Therapeutics Inc., a Delaware corporation (the “Company”), Mitchell Finer (the “Dr. Finer”), and Pattern Recognition Ventures (the “Consultant” and, collectively with the Company and Dr. Finer, the “Parties”).

TCR2 THERAPEUTICS INC. AMENDED AND RESTATED CONSULTING AGREEMENT

Consulting Agreement • September 7th, 2018 • Tcr2 Therapeutics Inc. • Biological products, (no disgnostic substances) • Massachusetts

• Contract Type
  Consulting Agreement
• Filed
  September 7th, 2018
• Company
  Tcr2 Therapeutics Inc.
• Industry
  Biological products, (no disgnostic substances)
• Jurisdiction
  Massachusetts

This Amended and Restated Consulting Agreement (the “Agreement”), made this 9th day of May, 2017 (“Effective Date”), is entered into by TCR2 Therapeutics Inc., a Delaware corporation (the “Company”), Mitchell Finer (the “Dr. Finer”), and Pattern Recognition Ventures (the “Consultant” and, collectively with the Company and Dr. Finer, the “Parties”).